3 unchanged sentences
001-38079), filed with the SEC on May 18, 2017).
−Removed: Form of June 2024 Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-38079), filed with the SEC on June 18, 2024).
−Removed: UroGen Pharma Ltd.
−Removed: 2019 Inducement Plan, as amended.
−Removed: UroGen Pharma Ltd.
−Removed: 2024 Non-Employee Director and Officer Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 8, 2024).
−Removed: 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 8, 2024).
+Added: Pre-Paid Forward Contract by and among the Registrant and RTW Investments ICAV for and on behalf of RTW Fund 2, dated as of March 18, 2021, as amended April 30, 2021 and August 14, 2024.
+Added: Separation Agreement between the Company and Don Kim, dated October 7, 2024 ( incorporated by reference to Exhibit 10.1 to the Registrant ’s Current Report on Form 8-K (File No.
+Added: 001-38079 ), filed with the SEC on October 9, 2024 ).
+Added: Employment Agreement between the Company and Chris Degnan, dated October 7, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant ’s Quarterly Report on form 10-Q (File No.
+Added: 001-38079 ), filed with the SEC on October 9, 2024) .
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL
−Removed: Management contract or compensatory plan.
+Added: Certain information in this exhibit has been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type of information that the registrant treats as private or confidential.
+Added: Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
1 unchanged sentence
UroGen Pharma Ltd.
−Removed: August 13, 2024
+Added: November 6, 2024
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 13, 2024
+Added: November 6, 2024
+Added: /s/ Chris Degnan
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.